285 related articles for article (PubMed ID: 33771453)
1. [Concurrent radiation therapy and dual HER2 blockade in breast cancer: Assessment of toxicity].
Ben Dhia S; Loap P; Loirat D; Vincent-Salomon A; Cao K; Escalup L; Fourquet A; Kirova Y
Cancer Radiother; 2021 Jul; 25(5):424-431. PubMed ID: 33771453
[TBL] [Abstract][Full Text] [Related]
2. Combination of radiotherapy and double blockade HER2 with pertuzumab and trastuzumab for HER2-positive metastatic or locally recurrent unresectable and/or metastatic breast cancer: Assessment of early toxicity.
Ajgal Z; de Percin S; Diéras V; Pierga JY; Campana F; Fourquet A; Kirova YM
Cancer Radiother; 2017 Apr; 21(2):114-118. PubMed ID: 28347625
[TBL] [Abstract][Full Text] [Related]
3. [Prospective monocentric study of the toxicity and the efficacy of concurrent trastuzumab and radiotherapy].
Jacob J; Belin L; Gobillion A; Daveau-Bergerault C; Dendale R; Beuzeboc P; Campana F; Bollet MA; Fourquet A; Kirova YM
Cancer Radiother; 2013 Jun; 17(3):183-90. PubMed ID: 23499212
[TBL] [Abstract][Full Text] [Related]
4. Potential impact of cardiac dose-volume on acute cardiac toxicity following concurrent trastuzumab and radiotherapy.
Cao L; Hu WG; Kirova YM; Yang ZZ; Cai G; Yu XL; Ma JL; Guo XM; Shao ZM; Chen JY
Cancer Radiother; 2014 Mar; 18(2):119-24. PubMed ID: 24642505
[TBL] [Abstract][Full Text] [Related]
5. [Preliminary results of whole breast helical tomotherapy with simultaneous integrated boost in the adjuvant treatment of breast cancer].
Liem X; Chira C; Fourquet A; Campana F; Peurien D; Fournier-Bidoz N; Kirova YM
Cancer Radiother; 2014 Jan; 18(1):15-22. PubMed ID: 24316350
[TBL] [Abstract][Full Text] [Related]
6. Concurrent trastuzumab with adjuvant radiotherapy in HER2-positive breast cancer patients: acute toxicity analyses from the French multicentric study.
Belkacémi Y; Gligorov J; Ozsahin M; Marsiglia H; De Lafontan B; Laharie-Mineur H; Aimard L; Antoine EC; Cutuli B; Namer M; Azria D
Ann Oncol; 2008 Jun; 19(6):1110-6. PubMed ID: 18344537
[TBL] [Abstract][Full Text] [Related]
7. Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial.
Hurvitz SA; Martin M; Symmans WF; Jung KH; Huang CS; Thompson AM; Harbeck N; Valero V; Stroyakovskiy D; Wildiers H; Campone M; Boileau JF; Beckmann MW; Afenjar K; Fresco R; Helms HJ; Xu J; Lin YG; Sparano J; Slamon D
Lancet Oncol; 2018 Jan; 19(1):115-126. PubMed ID: 29175149
[TBL] [Abstract][Full Text] [Related]
8. Cardiac Safety of Paclitaxel Plus Trastuzumab and Pertuzumab in Patients With HER2-Positive Metastatic Breast Cancer.
Yu AF; Manrique C; Pun S; Liu JE; Mara E; Fleisher M; Patil S; Jones LW; Steingart RM; Hudis CA; Dang CT
Oncologist; 2016 Apr; 21(4):418-24. PubMed ID: 26984450
[TBL] [Abstract][Full Text] [Related]
9. Pertuzumab and trastuzumab with or without metronomic chemotherapy for older patients with HER2-positive metastatic breast cancer (EORTC 75111-10114): an open-label, randomised, phase 2 trial from the Elderly Task Force/Breast Cancer Group.
Wildiers H; Tryfonidis K; Dal Lago L; Vuylsteke P; Curigliano G; Waters S; Brouwers B; Altintas S; Touati N; Cardoso F; Brain E
Lancet Oncol; 2018 Mar; 19(3):323-336. PubMed ID: 29433963
[TBL] [Abstract][Full Text] [Related]
10. Concurrent administration of trastuzumab with locoregional breast radiotherapy: long-term results of a prospective study.
Jacob J; Belin L; Pierga JY; Gobillion A; Vincent-Salomon A; Dendale R; Beuzeboc P; Campana F; Fourquet A; Kirova YM
Breast Cancer Res Treat; 2014 Nov; 148(2):345-53. PubMed ID: 25318926
[TBL] [Abstract][Full Text] [Related]
11. Trastuzumab, pertuzumab, and eribulin mesylate versus trastuzumab, pertuzumab, and a taxane as a first-line or second-line treatment for HER2-positive, locally advanced or metastatic breast cancer: study protocol for a randomized controlled, non-inferiority, phase III trial in Japan (JBCRG-M06/EMERALD).
Yamashita T; Masuda N; Saji S; Araki K; Ito Y; Takano T; Takahashi M; Tsurutani J; Koizumi K; Kitada M; Kojima Y; Sagara Y; Tada H; Iwasa T; Kadoya T; Iwatani T; Hasegawa H; Morita S; Ohno S
Trials; 2020 May; 21(1):391. PubMed ID: 32381018
[TBL] [Abstract][Full Text] [Related]
12. Cardiac function in women receiving dual anti-Her2 antibodies (trastuzumab and pertuzumab) combined with chemotherapy for breast cancer.
Zekri J; Rasool H; Rizvi SAJ; Eldeeb H; Al-Gahmi A; Farag K; Rasmy A
Womens Health (Lond); 2023; 19():17455057231166837. PubMed ID: 37148305
[TBL] [Abstract][Full Text] [Related]
13. Trastuzumab emtansine plus pertuzumab in Japanese patients with HER2-positive metastatic breast cancer: a phase Ib study.
Noguchi E; Tamura K; Hattori M; Horiguchi J; Sato N; Kanatani K; Matsunaga K; Iwata H; Fujiwara Y
Breast Cancer; 2019 Jan; 26(1):39-46. PubMed ID: 30039339
[TBL] [Abstract][Full Text] [Related]
14. Cardiac Safety of Dual Anti-HER2 Therapy in the Neoadjuvant Setting for Treatment of HER2-Positive Breast Cancer.
Yu AF; Singh JC; Wang R; Liu JE; Eaton A; Oeffinger KC; Steingart RM; Hudis CA; Dang CT
Oncologist; 2017 Jun; 22(6):642-647. PubMed ID: 28341761
[TBL] [Abstract][Full Text] [Related]
15. Cardiac toxicity and efficacy of trastuzumab combined with pertuzumab in patients with [corrected] human epidermal growth factor receptor 2-positive metastatic breast cancer.
Portera CC; Walshe JM; Rosing DR; Denduluri N; Berman AW; Vatas U; Velarde M; Chow CK; Steinberg SM; Nguyen D; Yang SX; Swain SM
Clin Cancer Res; 2008 May; 14(9):2710-6. PubMed ID: 18451236
[TBL] [Abstract][Full Text] [Related]
16. Toxicity of dual HER2-blockade with pertuzumab added to anthracycline versus non-anthracycline containing chemotherapy as neoadjuvant treatment in HER2-positive breast cancer: The TRAIN-2 study.
van Ramshorst MS; van Werkhoven E; Honkoop AH; Dezentjé VO; Oving IM; Mandjes IA; Kemper I; Smorenburg CH; Stouthard JM; Linn SC; Sonke GS;
Breast; 2016 Oct; 29():153-9. PubMed ID: 27498129
[TBL] [Abstract][Full Text] [Related]
17. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study.
Swain SM; Miles D; Kim SB; Im YH; Im SA; Semiglazov V; Ciruelos E; Schneeweiss A; Loi S; Monturus E; Clark E; Knott A; Restuccia E; Benyunes MC; Cortés J;
Lancet Oncol; 2020 Apr; 21(4):519-530. PubMed ID: 32171426
[TBL] [Abstract][Full Text] [Related]
18. [Monocentric evaluation of the skin and cardiac toxicities of the concomitant administration of trastuzumab and radiotherapy].
Kirova YM; Caussa L; Granger B; Savignoni A; Dendale R; Campana F; Tournat H; Pierga JY; Fourquet A; Bollet MA
Cancer Radiother; 2009 Jul; 13(4):276-80. PubMed ID: 19447661
[TBL] [Abstract][Full Text] [Related]
19. Early cardiac toxicity following adjuvant radiotherapy of left-sided breast cancer with or without concurrent trastuzumab.
Cao L; Cai G; Chang C; Yang ZZ; Feng Y; Yu XL; Ma JL; Wu J; Guo XM; Chen JY
Oncotarget; 2016 Jan; 7(1):1042-54. PubMed ID: 26460956
[TBL] [Abstract][Full Text] [Related]
20. The acute skin and heart toxicity of a concurrent association of trastuzumab and locoregional breast radiotherapy including internal mammary chain: a single-institution study.
Caussa L; Kirova YM; Gault N; Pierga JY; Savignoni A; Campana F; Dendale R; Fourquet A; Bollet MA
Eur J Cancer; 2011 Jan; 47(1):65-73. PubMed ID: 20843680
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
